-
Views
-
Cite
Cite
Vibegron, American Journal of Health-System Pharmacy, Volume 78, Issue 9, 1 May 2021, Pages 764–765, https://doi.org/10.1093/ajhp/zxab037
- Share Icon Share
Extract
Vibegron is a selective β3-adrenergic agonist.
Class: 86:12.08.12 • Selective beta-3 Adrenergic Agonists (AHFS primary) Brands: Gemtesa®
Uses
Vibegron has the following uses:
...
Dosage and Administration
General.
Vibegron is available in the following dosage form(s) and strength(s): Tablets: 75 mg.
Dosage.
It is essential that the manufacturer’s labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
Adults.
Dosage and Administration.
...
Cautions
Contraindications.
Do not use if prior hypersensitivity reaction to vibegron or any components of the product.
Warnings/Precautions.
Urinary Retention.
Urinary retention has been reported in patients taking vibegron. The risk of urinary retention may be increased in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for the treatment of OAB. Monitor patients for signs and symptoms of urinary retention, particularly in patients with bladder outlet obstruction and patients taking muscarinic antagonist medications for the treatment of OAB. Discontinue vibegron in patients who develop urinary retention.
Comments